



Introduction: Measurement and monitoring of blood glucose levels in hospitalized patients with portable glucose meters (PGMs) is performed 
widely and is an essential part of diabetes monitoring, despite the increasing evidence of several interferences which can negatively bias the accu-
racy of measurements. The purpose of this study was to evaluate the eff ect of the hematocrit on the analytical performances of diff erent PGMs as 
compared with a reference laboratory assay.
Materials and methods: The eff ect of various hematocrit values (~0.20, ~0.45 and ~0.63 L/L) were assessed in three whole blood specimens 
with diff erent glucose concentration (~1.1, ~13.3, and ~25 mmol/L) by using six diff erent commercial PGMs. The identical samples were also tested 
with the laboratory reference assay (i.e., hexokinase). The percentage diff erence from the laboratory assay (%Diff ) was calculated as follows: % Diff  
= average PGM value - value from laboratory assay x 100 / value from laboratory assay.
Results: The %Diff  of the six diff erent PGMs were rather broad, and comprised between 56.5% and -34.8% in the sample with low glucose con-
centration (~1.1 mmol/L), between 40% and -32% in the sample with high glucose concentration (~13.3 mmol/L), and between –50% and 15% in 
the sample with very high glucose concentration (~25 mmol/L), respectively. It is also noteworthy that a very high hematocrit value (up to 0.63 L/L) 
generated a remarkable negative bias in blood glucose (-35%) as measured with the laboratory assay, when compared with the reference sample 
(hematocrit 0.45 L/L).
Conclusion: The results of this analytical evaluation clearly confi rm that hematocrit produces a strong and almost unpredictable bias on PGMs 
performances, which is mainly dependent on the diff erent type of devices. As such, the healthcare staff  and the patients must be aware of this limi-
tation, especially in the presence of extreme hematocrit levels, when plasma glucose assessment with the reference laboratory technique might be 
advisable.
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Introduction
The chronic hyperglycaemia of diabetes mellitus is 
associated with long-term organ dysfunction and 
increased risk of complications such as cardiovas-
cular disease, renal failure, retinal and neurological 
diseases (1). Regular monitoring of blood glucose 
along with appropriate pharmacological treat-
ment are eff ective to improve the glycaemic con-
trol and thereby decrease the burden of long term 
complications of hyperglycaemia (2). In agreement 
with the current position of the American Diabe-
tes Association (ADA), self-monitoring of blood 
glucose (SMBG) is recommended for all patient un-
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dergoing insulin therapy (3). In particular, ADA sug-
gests that SMBG should be used in patients on in-
tensive insulin therapy, in patients not in pharma-
cological treatment but in diet therapy alone to 
achieve an optimal glycaemia control, and to 
achieve the optimal postprandial glycaemic target 
(4). The National Academy of Clinical Biochemistry 
(NACB) also recommends that SMBG should be 
made available to all diabetic patients on insulin 
therapy (5). Portable glucose meters (PGMs) are 
widely used by patients for home testing, and de-
spite these devices are fast and easy to use, the pa-
tients must be trained on the correct handling. 
Moreover, PGMs are currently used in other clinical 
settings, including departments of acute and 
chronic care (hospital, clinics) as well as internal 
medical wards to monitor hypoglycaemic therapy 
in diabetics and patients with acute myocardial in-
farction. In internal medicine wards, PGMs are used 
directly by the healthcare staff , which should be 
appropriately trained to their use and mainte-
nance, so that the risk of improper application can 
be eliminated or limited at least. Nevertheless, 
some variables can aff ect the effi  cacy of glucose 
monitoring by PGM also in this setting, including 
the hematocrit level, hypoxemia, hypotension, 
hypertriglyceridemia, temperature and humidity 
of the environment (6). The purpose of this study 
was to evaluate the interference of the hematocrit 
on the analytical performances of diff erent PGMs 
as compared with the laboratory measurement.
Material and methods
Samples
To evaluate the eff ect of hematocrit on reliability 
of PGM test result, three diff erent hematocrit lev-
els (0.22, 0.45 and 0.62 L/L) were studied. Three 
levels of glucose (target ranges as ~20 mg/dL, ~240 
mg/dL and ~450 mg/dL; i.e., ~1.1 mmol/L; ~13.3 
mmol/L and ~25 mmol/L) were assessed. We ob-
tained discarded venous blood collected in 
heparin tubes without separator gel (Venosafe, 
Terumo Europe, Leuven, Belgium) from healthy 
donors. Assuming that samples with very low glu-
cose concentrations are not easily available, these 
were obtained by collecting the blood the day be-
fore the evaluation and maintained the whole an-
ticoagulated blood on a rocker to allow consump-
tion of glucose. We ensured the blood was satu-
rated with oxygen by opening the tubes. After-
wards, a glucose stock solution (Concentration 20 
g/dL) supplied by Nova Biomedical Corporation 
(Waltham, CA, USA) (i.e., the addition of 7.5 μL of 
glucose spiking solution to a 1 mL whole blood 
sample increases the glucose concentration by 8.3 
mmol/L) was spiked into each blood collection 
tube to obtain the target glucose ranges and the 
blood tubes were then placed on blood tubes 
rocker for 10 minutes to allow adequate mixing.
Methods
The initial hematocrit of the stock blood (i.e., 0.469 
L/L) was assessed on a hematological analyzer 
(Coulter LH750 Analyser, Beckman Coulter, Fuller-
ton, CA, USA). In our laboratory the reference in-
terval of hematocrit values are 0.37-0.47 L/L for fe-
males and 0.42-0.52 L/L for males, respectively. 
Three aliquots of 1 mL samples were thereby pre-
pared (labelled as A1, A2, A3) by adding fi xed 
amount of packed red blood cells and plasma to 
achieve fi nal hematocrit concentrations in the 
tubes as follows: A1: 0.22; A2: 0.45; A3: 0.62 L/L. The 
tubes were then placed on tube rocker for 10 min-
utes and glucose was tested afterwards with six 
PGMs and, after centrifugation of the samples 
(then minutes at 3500 rpm), by the reference labo-
ratory assay (i.e., hexokinase, Olympus AU 2700, 
Beckman Coulter, Fullerton, CA, USA). Table 1 
shows the main characteristics of the PGMs used 
in this study (Accu-Chek Compact Plus Roche Di-
agnostics GmbH, Mannheim, Germany; Breeze2 
Bayer, Basel, Switzerland; One touch Vita, Life Scan 
Inc., Milpitas, CA, USA; Optium Xceed Abbott Dia-
betes Care, Oxon, UK; Ratisbonne BGM, Acon Lab-
oratories Inc. San Diego, CA, USA; Stat-Strip Xpress 
Nova Biomedical, Waltham,CA, USA). Only one test 
strip lot was used for each PGMs. The PGMs and 
the laboratory assay were all calibrated according 
to manufacturer’s instruction. All the measure-
ments were performed simultaneously (within 10 
min) in duplicate by two skilled laboratory tech-
nologists.




The % diff erence from laboratory method (%Diff ) 
was calculated by the average glucose measure-
ment of each duplicate obtained from each PGM 
from the value obtained by the laboratory method 
(i.e., % Diff  = average PGM value - value from the 
reference laboratory assay x 100 / value the refer-
ence laboratory assay).
Results
The results of this investigation are shown in fi g-
ures 1, 2 and 3 and in tables 2, 3 and 4. At low glu-
cose concentration (~1.1 mmol/L) the %Diff  from 
the value obtained by the laboratory method are 
comprised between 56.5% and -34.8%. Among 
the diff erent PGMs, the Stat-Strip Xpress shows the 
best performance in comparison with the refer-
ence laboratory assay (%Diff  between -4.3 and 
+8.7). It is however noteworthy that the bias of 
some PGMs (as compared with the reference labo-
ratory assay) at normal hematocrit level and very 
low glucose concentration was broad and clinical-
ly meaningful (Figure 1).
GPMs Manufacturer Detection systems Enzyme 
Stat-Strip Xpress Nova Biomedical Electrochemistry Glucose oxidase
Accu-Chek Compact Plus Roche Diagnostics GmbH Optical Glucose oxidase
Ratisbonne BGM Acon Laboratories Inc. Not stated Not stated
One touch Vita Life Scan Inc. Electrochemistry Glucose oxidase
Breeze2 Bayer Electrochemistry Glucose oxidase
Optium Xceed Abbott Diabetes Care Electrochemistry Glucose dehydrogenase
TABLE 1. Characteristic of the GPMs used in this study.
HcT = 0.22 L/L HcT = 0.45 L/L HcT = 0.63 L/L
Glucose (mmol/L) %Diff Glucose (mmol/L) %Diff Glucose (mmol/L) %Diff 
Stat-Strip 1.28 0 1.39 8.7 1.22 -4.3
Accu-Chek 1.39 4.3 2.00 56.5 1.10 -13.0
Ratisbone 1.00 -21.7 2.00 56.5 1.05 -17.4
One touch 1.00 -21.7 1.90 47.8 1.10 -13.0
Breeze2 0.80 -34.8 1.70 30.4 1.05 -17.4
Optium Xceed 1.00 -21.7 1.40 13 1.00 -21.7
TABLE 2. Glucose measurement (mean of two replicates) and %Diff  on sample with low glucose concentration. Value from laboratory 
method 1.28 mmol/L (as mean of two replicate in the sample with hematocrit 0.45 L/L).
At high glucose concentration (~13.3 mmol/L) the 
%Diff  were comprised between -32% and +40%. 
In such case, the modest performance by PGMs is 
conceivably attributable to the eff ect of high lev-
els of hematocrit. Interestingly, the observed bias 
of PGMs was mostly negative (i.e., from -32% to 
-17%), with the only exception of the Ratisbonne 
(+40%). The Stat-Strip Xpress and the Accu-Chek 
showed the best performance in comparison with 
the laboratory assay (Figure 2).
At very high glucose concentration (~25 mmol/L), 
the %Diff  was comprised between -50% and 15%. 
(Figure 3). As expected, the great diff erence from 
the reference laboratory assay was again attribut-
able to the infl uence of extremely high hematocrit 
level. Even more interestingly, the sample with he-
matocrit value up to 0.63 also produced a remark-
able bias using the laboratory technique, since the 
sample with a theoretically glucose concentration 
of 25 mmol/L yielded instead a fi nal value of 16 
mmol/L (i.e., -35%).
Daves M. et al. Hematocrit bias on portable glucose meters
Biochemia Medica 2011;21(3):306–11
  309
HcT = 0.22 L/L HcT = 0.45 L/L HcT = 0.63 L/L
Glucose (mmol/L) %Diff Glucose (mmol/L) %Diff Glucose (mmol/L) %Diff 
Stat-Strip 13.7 1.6 13.8 2.0 14.4 6.6
Accu-Chek 14.8 9.9 13.6 1.2 11.0 -18.5
Ratisbone 13.38 -0.8 15.6 15.0 18.6 38.0
One touch 15.0 11 12.5 -7.0 9.1 -32.0
Breeze2 15.3 13 11.8 -12.0 9.1 -32.0
Optium Xceed 12.6 -6.6 13.7 1.6 10.4 -22.6
HcT = 0.22 L/L HcT = 0.45 L/L HcT = 0.63 L/L
Glucose (mmol/L) %Diff Glucose (mmol/L) %Diff Glucose (mmol/L) %Diff 
Stat-Strip 22.5 -11 25.7 1.7 15.5 -38.0
Accu-Chek 23.9 -5.3 25.4 0.6 12.3 -51.0
Ratisbone 21.2 -16.0 26.7 6.0 17.1 -32.0
One touch 23.5 -7.0 22.0 13.0 14.7 -42.0
Breeze2 24.0 -4.8 22.3 -10.0 14.9 -41.0
Optium Xceed 19.0 -24.0 16.8 -33.0 12.6 -49.0
FIGURE 1. %Diff  from laboratory method at diff erent hematocrit 
levels (0.22, 0.45 and 0.63 L/L) in the sample with very low glu-
cose concentration (~1.1 mmol/L).
FIGURE 2. %Diff  from laboratory method at diff erent hematocrit 
levels (0.22, 0.45 and 0.63 L/L) in the sample with high glucose 
concentration (~13.3 mmol/L).
TABLE 3. Glucose measurement (mean of two replicates) and %Diff  on sample with high glucose concentration. Value from labora-
tory method 13.4 mmol/L (as mean of two replicate in the sample with hematocrit = 0.45 L/L.
TABLE 4. Glucose measurement (mean of two replicates) and %Diff  on sample with very high glucose concentration. Value from labo-
ratory method 25.2 mmol/L (as mean of two replicate in the sample with hematocrit = 0.45 L/L.
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Preanalytical variability and analytical quality both 
have a strong infl uence on the reliability of labora-
tory testing, on common laboratory assays (7-11) 
and point of care testing (POCT) (12).
The revised Clinical and Laboratory Standards In-
stitute (CLSI, the former National Committee for 
Clinical Laboratory Standards) guidelines (9), and 
further adopted by the International Organization 
for Standardization (ISO), recommend that less 
than 5% of the samples should have a bias of ± 
0.83 mmol/L (for glucose concentrations < 4.2 
mmolL), or within ± 20% (for glucose concentra-
tions > 4.2 mmol/L), when compared with the ref-
erence laboratory assay. Therefore the results of 
this analytical investigation confi rm that the hema-
tocrit value can substantially bias glucose measure-
ments on PGMs and reference laboratory assay, 
producing a bias that largely exceed the quality re-
quirements established by the CLSI and which can 
thereby be considered clinically signifi cant. Note-
worthy, the hematocrit bias appeared extremely 
heterogeneous and mostly unpredictable among 
the diff erent PGMs, with diff erences as high as 40%. 
This fi nding has substantial clinical implication for 
both the clinical decision making and the thera-
peutic management, especially in subjects who 
are characterized by unusually high or low hemat-
ocrit values, such as newborns and critically ill pa-
tients, respectively. In particular, we have shown 
that this bias is also evident in samples with very 
low glucose levels (i.e., ~1.1 mmol/L) as compared 
with the reference laboratory technique (Figure 1). 
Recently Roth-Kleiner report that before daily use 
in the newborn population, careful clinical evalua-
tion of each new POCT system for glucose meas-
urement is of utmost importance, concluding that 
the bench analyzer ABL 735 was the most accurate 
system, being however characterized by an impor-
tant drawback (i.e., the blood volume needed is 
more than 15 times higher than for handheld 
PGMs) (13). So, the users of PGMs (both the health-
care personnel and the patients) must be aware of 
this limitation and, as recommended by Tang et al. 
(14), we suggest that clinicians must interpret with 
great caution the results obtained with PGMs in 
patients with abnormal (especially very high or 
very low) hematocrit levels. In these circumstanc-
es, the measurement of plasma glucose using the 
laboratory technique might be advisable.
Although the mechanism underlying the preana-
lytical interference of hematocrit has not been ful-
ly established, it has however been suggested that 
the presence of an increased number of red blood 
cells might (mechanically) prevent the diff usion of 
plasma through the layers of the test strips, there-
by decreasing the volume of plasma available for 
the enzymatic reaction (6). This interference has 
been eliminated in some PGMs that measure he-
matocrit along with glucose in the drop of blood, 
operating a further correction of test results (15). 
Some authors have also developed a simple math-
ematical correction formula for some commonly 
used PGMs used in the United States that is eff ec-
tive to reduce, as claimed by the authors, the inac-
curacy caused by anemia (16,17). More recently, 
Hoedemaekers et al. failed to observe an eff ect of 
hematocrit on the accuracy of PGMs performance 
in critically ill patients (18).
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FIGURE 3. %Diff  from laboratory method at diff erent hematocrit 
levels (0.22, 0.45 and 0.63 L/L) in the sample with very high glu-
cose concentration (~25 mmol/L).
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Procjena pogreške zbog hematokrita prilikom mjerenja koncentracije glukoze 
u krvi primjenom šest različitih prijenosnih glukometara
Sažetak
Uvod: Mjerenje i praćenje koncentracije glukoze u krvi kod hospitaliziranih bolesnika prijenosnim glukometrom (engl. portable glucose meters, 
PGMs) u širokoj je primjeni te predstavlja ključan dio liječenja šećerne bolesti, usprkos prisustvu nekoliko vrsta interferencija koje mogu uzroko-
vati negativnu pogrešku prilikom mjerenja. Svrha ovog istraživanja je procijeniti utjecaj hematokrita na analitički rad različitih PGM u usporedbi 
s referentnom laboratorijskom metodom.
Materijali i metode: Utjecaj različitih vrijednosti hematokrita (0,20, 0,45 i 0,63 L/L) procijenjen je u tri uzorka pune krvi s različitom koncen-
tracijom glukoze (~1,1, ~13,3 i ~25,0 mmol/L) primjenom šest različitih komercijalnih PGM. Isti su uzorci ispitivani referentnom laboratorijskom 
metodom (heksokinazom). Postotak razlike u odnosu na laboratorijsku metodu (%Diff ) izračunat je na sljedeći način: %Diff  = prosječna vrijed-
nost dobivena PGM – vrijednost dobivena laboratorijskom metodom x 100 / vrijednost dobivena laboratorijskom metodom.
Rezultati: %Diff  između šest različitih PGM bila je širokog raspona i iznosila između 56,5% do -34,8% kod uzoraka s niskom koncentracijom glukoze 
(~1,1 mmol/L), između 40% i -32% kod uzoraka s visokom koncentracijom glukoze (~13,3 mmol/L) i između -50% i 15% kod uzoraka s vrlo visokom 
koncentracijom glukoze (~25,0 mmol/L). Također je značajan podatak da je vrlo visoka vrijednost hematokrita (0,63 L/L) stvorila značajno negativnu 
pogrešku kod određivanja koncentracije glukoze u krvi (-35%) laboratorijskom metodom u usporedbi s referentnim uzorkom (hematokrit 0,45 L/L).
Zaključak: Rezultati ovog analitičkog istraživanja jasno potvrđuju da hematokrit stvara jaku i gotovo nepredvidivu pogrešku u primjeni PGM 
što uglavnom ovisi o različitom tipu uređaja. Zdravstveno osoblje i bolesnici moraju biti svjesni tog ograničenja pogotovo kod pojave ekstremne 
razine hematokrita kada se preporuča određivanje koncentracije glukoze u plazmi referentnim laboratorijskim metodama.
Ključne riječi: prijenosni glukometar; pogreška; hematokrit; analitički rad
